Robeco Institutional Asset Management B.V. Sells 501,987 Shares of Johnson & Johnson (NYSE:JNJ)

Robeco Institutional Asset Management B.V. reduced its stake in Johnson & Johnson (NYSE:JNJ) by 41.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 723,071 shares of the company’s stock after selling 501,987 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Johnson & Johnson were worth $1,193,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. Dock Street Asset Management Inc. raised its holdings in shares of Johnson & Johnson by 25.9% in the third quarter. Dock Street Asset Management Inc. now owns 3,276 shares of the company’s stock worth $510,000 after buying an additional 674 shares during the last quarter. Perfromance Wealth Partners LLC raised its holdings in shares of Johnson & Johnson by 1.3% in the third quarter. Perfromance Wealth Partners LLC now owns 53,086 shares of the company’s stock worth $8,268,000 after buying an additional 660 shares during the last quarter. SC&H Financial Advisors Inc. raised its holdings in shares of Johnson & Johnson by 5.1% in the third quarter. SC&H Financial Advisors Inc. now owns 2,149 shares of the company’s stock worth $335,000 after buying an additional 105 shares during the last quarter. Choate Investment Advisors raised its holdings in shares of Johnson & Johnson by 13.6% in the third quarter. Choate Investment Advisors now owns 90,366 shares of the company’s stock worth $14,075,000 after buying an additional 10,822 shares during the last quarter. Finally, Strengthening Families & Communities LLC raised its holdings in shares of Johnson & Johnson by 6.9% in the third quarter. Strengthening Families & Communities LLC now owns 15,243 shares of the company’s stock worth $2,374,000 after buying an additional 981 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on JNJ shares. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Royal Bank of Canada reissued an “outperform” rating and set a $175.00 target price on shares of Johnson & Johnson in a report on Wednesday. Morgan Stanley reduced their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a report on Wednesday, April 17th. HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and raised their target price for the stock from $169.00 to $170.00 in a report on Thursday, April 18th. Finally, Bank of America reduced their target price on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. Seven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $175.86.

Johnson & Johnson Stock Up 1.5 %

Shares of NYSE JNJ opened at $153.52 on Thursday. The company’s 50-day simple moving average is $151.73 and its 200-day simple moving average is $155.11. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $175.97. The firm has a market cap of $369.47 billion, a price-to-earnings ratio of 9.57, a price-to-earnings-growth ratio of 2.51 and a beta of 0.55. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $0.07. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The business had revenue of $21.38 billion for the quarter, compared to analyst estimates of $21.39 billion. During the same quarter last year, the business earned $2.68 earnings per share. The company’s revenue for the quarter was up 2.3% compared to the same quarter last year. Equities analysts predict that Johnson & Johnson will post 10.64 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Monday, May 20th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.19. This represents a $4.96 dividend on an annualized basis and a yield of 3.23%. Johnson & Johnson’s payout ratio is presently 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.